S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968120.02996.d3 |
| _version_ | 1797281715984531456 |
|---|---|
| author | Monica Carpenedo Catherine M Broome Vickie Mcdonald Yoshitaka Miyakawa David Kuter Hanny Al-Samkari James Bussel Filip Matthijssens Anna Hultberg Jaume Ayguasanosa Dachs Kristof De Beuf Francesco Rodeghiero Marc Michel Adrian Newland |
| author_facet | Monica Carpenedo Catherine M Broome Vickie Mcdonald Yoshitaka Miyakawa David Kuter Hanny Al-Samkari James Bussel Filip Matthijssens Anna Hultberg Jaume Ayguasanosa Dachs Kristof De Beuf Francesco Rodeghiero Marc Michel Adrian Newland |
| author_sort | Monica Carpenedo |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:01:27Z |
| format | Article |
| id | doaj.art-ec588614d5f4449cb0dc895160e3537b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:01:27Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-ec588614d5f4449cb0dc895160e3537b2024-03-03T03:24:16ZengWileyHemaSphere2572-92412023-08-017e02996d310.1097/01.HS9.0000968120.02996.d3202308003-00204S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDYMonica Carpenedo0Catherine M Broome1Vickie Mcdonald2Yoshitaka Miyakawa3David Kuter4Hanny Al-Samkari5James Bussel6Filip Matthijssens7Anna Hultberg8Jaume Ayguasanosa Dachs9Kristof De Beuf10Francesco Rodeghiero11Marc Michel12Adrian Newland131 U.O.C Hematology and Transplant Unit Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy2 Georgetown University, Washington, United States3 Barts Health NHS Trust, London, United Kingdom4 Saitama Medical University Hospital, Saitama, Japan5 Massachusetts General Hospital, Hematology Division, Boston, United States5 Massachusetts General Hospital, Hematology Division, Boston, United States6 Weill Cornell Medical College, New York, United States7 argenx, Ghent, Belgium7 argenx, Ghent, Belgium7 argenx, Ghent, Belgium7 argenx, Ghent, Belgium8 Haematology Project Foundation, Affiliated to the Department of Haematology, S. Bortolo Hospital, Vicenza, Italy9 Department of Internal Medicine, National Reference Center for Immune Cytopenias, Henri Mondor University Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France10 Centre for Haematology, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000968120.02996.d3 |
| spellingShingle | Monica Carpenedo Catherine M Broome Vickie Mcdonald Yoshitaka Miyakawa David Kuter Hanny Al-Samkari James Bussel Filip Matthijssens Anna Hultberg Jaume Ayguasanosa Dachs Kristof De Beuf Francesco Rodeghiero Marc Michel Adrian Newland S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY HemaSphere |
| title | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_full | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_fullStr | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_full_unstemmed | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_short | S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY |
| title_sort | s302 long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia interim results of the advance study |
| url | http://journals.lww.com/10.1097/01.HS9.0000968120.02996.d3 |
| work_keys_str_mv | AT monicacarpenedo s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT catherinembroome s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT vickiemcdonald s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT yoshitakamiyakawa s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT davidkuter s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT hannyalsamkari s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT jamesbussel s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT filipmatthijssens s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT annahultberg s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT jaumeayguasanosadachs s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT kristofdebeuf s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT francescorodeghiero s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT marcmichel s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy AT adriannewland s302longtermsafetyandefficacyofefgartigimodinpatientswithprimaryimmunethrombocytopeniainterimresultsoftheadvancestudy |